CZ292002B6 - Léčivo pro snížení úmrtnosti způsobené městnavým selháním srdce u savců - Google Patents

Léčivo pro snížení úmrtnosti způsobené městnavým selháním srdce u savců Download PDF

Info

Publication number: CZ292002B6
Authority: CZ; Czechia
Prior art keywords: carvedilol; medicament; manufacture; dose; administered
Prior art date: 1995-02-08

Application number

CZ19972463A

Other languages

Czech (cs)

English (en)

Other versions

CZ246397A3 (cs

Inventor

Mary Ann Lukas-Laskey

Robert Ruffolo Jr.

Neil Shusterman

Gisbert Sponer

Klaus Strein

Original Assignee

Boehringer Mannheim Pharmaceuticals Corporation Sm

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-02-08

Filing date

1996-02-07

Publication date

2003-07-16

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26012210&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CZ292002(B6) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1995-02-08 Priority claimed from DE1995103995 external-priority patent/DE19503995C2/de

1996-02-07 Application filed by Boehringer Mannheim Pharmaceuticals Corporation Sm filed Critical Boehringer Mannheim Pharmaceuticals Corporation Sm

1998-11-11 Publication of CZ246397A3 publication Critical patent/CZ246397A3/cs

2003-07-16 Publication of CZ292002B6 publication Critical patent/CZ292002B6/cs

Links

206010019280 Heart failures Diseases 0.000 title claims abstract description 46
206010007559 Cardiac failure congestive Diseases 0.000 title claims abstract description 41
239000003814 drug Substances 0.000 title claims abstract description 29
241000124008 Mammalia Species 0.000 title claims abstract description 7
230000003247 decreasing effect Effects 0.000 title abstract description 5
NPAKNKYSJIDKMW-UHFFFAOYSA-N carvedilol Chemical compound COC1=CC=CC=C1OCCNCC(O)COC1=CC=CC2=NC3=CC=C[CH]C3=C12 NPAKNKYSJIDKMW-UHFFFAOYSA-N 0.000 claims abstract description 57
229960004195 carvedilol Drugs 0.000 claims abstract description 55
239000002934 diuretic Substances 0.000 claims abstract description 14
229940097217 cardiac glycoside Drugs 0.000 claims abstract description 12
239000002368 cardiac glycoside Substances 0.000 claims abstract description 12
229930002534 steroid glycoside Natural products 0.000 claims abstract description 12
229940030606 diuretics Drugs 0.000 claims abstract description 11
150000003839 salts Chemical class 0.000 claims abstract description 8
150000008143 steroidal glycosides Chemical class 0.000 claims abstract description 8
229940124597 therapeutic agent Drugs 0.000 claims abstract description 6
239000003112 inhibitor Substances 0.000 claims abstract description 5
238000011282 treatment Methods 0.000 claims description 24
238000012423 maintenance Methods 0.000 claims description 20
238000004519 manufacturing process Methods 0.000 claims description 14
239000005541 ACE inhibitor Substances 0.000 claims description 9
229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 claims description 9
239000008194 pharmaceutical composition Substances 0.000 claims description 9
LTMHDMANZUZIPE-AMTYYWEZSA-N Digoxin Natural products O([C@H]1[C@H](C)O[C@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@](C)([C@H](O)C4)[C@H](C4=CC(=O)OC4)CC5)CC3)CC2)C[C@@H]1O)[C@H]1O[C@H](C)[C@@H](O[C@H]2O[C@@H](C)[C@H](O)[C@@H](O)C2)[C@@H](O)C1 LTMHDMANZUZIPE-AMTYYWEZSA-N 0.000 claims description 5
108010061435 Enalapril Proteins 0.000 claims description 5
229960005156 digoxin Drugs 0.000 claims description 5
LTMHDMANZUZIPE-PUGKRICDSA-N digoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O LTMHDMANZUZIPE-PUGKRICDSA-N 0.000 claims description 5
LTMHDMANZUZIPE-UHFFFAOYSA-N digoxine Natural products C1C(O)C(O)C(C)OC1OC1C(C)OC(OC2C(OC(OC3CC4C(C5C(C6(CCC(C6(C)C(O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)CC2O)C)CC1O LTMHDMANZUZIPE-UHFFFAOYSA-N 0.000 claims description 5
GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 claims description 5
229960000873 enalapril Drugs 0.000 claims description 5
JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 claims description 4
FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 claims description 4
229960000830 captopril Drugs 0.000 claims description 4
229960002003 hydrochlorothiazide Drugs 0.000 claims description 4
LPMXVESGRSUGHW-HBYQJFLCSA-N ouabain Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@@H]1C[C@@]2(O)CC[C@H]3[C@@]4(O)CC[C@H](C=5COC(=O)C=5)[C@@]4(C)C[C@@H](O)[C@@H]3[C@@]2(CO)[C@H](O)C1 LPMXVESGRSUGHW-HBYQJFLCSA-N 0.000 claims description 4
BIDNLKIUORFRQP-XYGFDPSESA-N (2s,4s)-4-cyclohexyl-1-[2-[[(1s)-2-methyl-1-propanoyloxypropoxy]-(4-phenylbutyl)phosphoryl]acetyl]pyrrolidine-2-carboxylic acid Chemical compound C([P@@](=O)(O[C@H](OC(=O)CC)C(C)C)CC(=O)N1[C@@H](C[C@H](C1)C1CCCCC1)C(O)=O)CCCC1=CC=CC=C1 BIDNLKIUORFRQP-XYGFDPSESA-N 0.000 claims description 3
101710129690 Angiotensin-converting enzyme inhibitor Proteins 0.000 claims description 3
101710086378 Bradykinin-potentiating and C-type natriuretic peptides Proteins 0.000 claims description 3
108010007859 Lisinopril Proteins 0.000 claims description 3
230000001882 diuretic effect Effects 0.000 claims description 3
229960002490 fosinopril Drugs 0.000 claims description 3
229960002394 lisinopril Drugs 0.000 claims description 3
RLAWWYSOJDYHDC-BZSNNMDCSA-N lisinopril Chemical compound C([C@H](N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(O)=O)C(O)=O)CC1=CC=CC=C1 RLAWWYSOJDYHDC-BZSNNMDCSA-N 0.000 claims description 3
229960003746 metildigoxin Drugs 0.000 claims description 3
IYJMSDVSVHDVGT-PEQKVOOWSA-N metildigoxin Chemical compound O1[C@H](C)[C@@H](OC)[C@@H](O)C[C@@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O IYJMSDVSVHDVGT-PEQKVOOWSA-N 0.000 claims description 3
229960005461 torasemide Drugs 0.000 claims description 3
108010064733 Angiotensins Proteins 0.000 claims description 2
102000015427 Angiotensins Human genes 0.000 claims description 2
NGBFQHCMQULJNZ-UHFFFAOYSA-N Torsemide Chemical compound CC(C)NC(=O)NS(=O)(=O)C1=CN=CC=C1NC1=CC=CC(C)=C1 NGBFQHCMQULJNZ-UHFFFAOYSA-N 0.000 claims description 2
229960003883 furosemide Drugs 0.000 claims description 2
ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 claims description 2
239000002552 dosage form Substances 0.000 claims 3
239000000126 substance Substances 0.000 claims 3
102000004190 Enzymes Human genes 0.000 claims 1
108090000790 Enzymes Proteins 0.000 claims 1
239000003795 chemical substances by application Substances 0.000 abstract description 6
238000002360 preparation method Methods 0.000 abstract description 2
UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 abstract 2
102000004270 Peptidyl-Dipeptidase A Human genes 0.000 abstract 2
108090000882 Peptidyl-Dipeptidase A Proteins 0.000 abstract 2
230000009467 reduction Effects 0.000 description 15
150000001875 compounds Chemical class 0.000 description 14
239000000902 placebo Substances 0.000 description 14
229940068196 placebo Drugs 0.000 description 14
238000002474 experimental method Methods 0.000 description 8
239000000203 mixture Substances 0.000 description 8
230000037081 physical activity Effects 0.000 description 8
230000000694 effects Effects 0.000 description 7
230000000302 ischemic effect Effects 0.000 description 7
238000004458 analytical method Methods 0.000 description 6
235000002639 sodium chloride Nutrition 0.000 description 6
239000004480 active ingredient Substances 0.000 description 5
238000009472 formulation Methods 0.000 description 5
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
201000010099 disease Diseases 0.000 description 4
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
208000019622 heart disease Diseases 0.000 description 4
230000006872 improvement Effects 0.000 description 4
239000007788 liquid Substances 0.000 description 4
-1 oxygen radical Chemical class 0.000 description 4
230000004083 survival effect Effects 0.000 description 4
208000024891 symptom Diseases 0.000 description 4
230000001225 therapeutic effect Effects 0.000 description 4
206010002383 Angina Pectoris Diseases 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
230000000903 blocking effect Effects 0.000 description 3
239000000969 carrier Substances 0.000 description 3
230000001684 chronic effect Effects 0.000 description 3
239000013065 commercial product Substances 0.000 description 3
230000034994 death Effects 0.000 description 3
231100000517 death Toxicity 0.000 description 3
238000007911 parenteral administration Methods 0.000 description 3
238000012216 screening Methods 0.000 description 3
239000007787 solid Substances 0.000 description 3
239000006188 syrup Substances 0.000 description 3
235000020357 syrup Nutrition 0.000 description 3
238000012360 testing method Methods 0.000 description 3
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
IZHVBANLECCAGF-UHFFFAOYSA-N 2-hydroxy-3-(octadecanoyloxy)propyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)COC(=O)CCCCCCCCCCCCCCCCC IZHVBANLECCAGF-UHFFFAOYSA-N 0.000 description 2
208000000059 Dyspnea Diseases 0.000 description 2
206010013975 Dyspnoeas Diseases 0.000 description 2
108010010803 Gelatin Proteins 0.000 description 2
206010020772 Hypertension Diseases 0.000 description 2
240000007472 Leucaena leucocephala Species 0.000 description 2
235000010643 Leucaena leucocephala Nutrition 0.000 description 2
206010033557 Palpitations Diseases 0.000 description 2
230000003276 anti-hypertensive effect Effects 0.000 description 2
239000002876 beta blocker Substances 0.000 description 2
229940097320 beta blocking agent Drugs 0.000 description 2
102000015005 beta-adrenergic receptor activity proteins Human genes 0.000 description 2
108040006818 beta-adrenergic receptor activity proteins Proteins 0.000 description 2
230000037396 body weight Effects 0.000 description 2
230000000747 cardiac effect Effects 0.000 description 2
239000003085 diluting agent Substances 0.000 description 2
231100000673 dose–response relationship Toxicity 0.000 description 2
239000003937 drug carrier Substances 0.000 description 2
239000000839 emulsion Substances 0.000 description 2
235000019441 ethanol Nutrition 0.000 description 2
206010016256 fatigue Diseases 0.000 description 2
229920000159 gelatin Polymers 0.000 description 2
239000008273 gelatin Substances 0.000 description 2
239000007903 gelatin capsule Substances 0.000 description 2
235000019322 gelatine Nutrition 0.000 description 2
235000011852 gelatine desserts Nutrition 0.000 description 2
238000000227 grinding Methods 0.000 description 2
238000003018 immunoassay Methods 0.000 description 2
239000012669 liquid formulation Substances 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
238000002156 mixing Methods 0.000 description 2
239000001788 mono and diglycerides of fatty acids Substances 0.000 description 2
239000000047 product Substances 0.000 description 2
230000000284 resting effect Effects 0.000 description 2
208000013220 shortness of breath Diseases 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
238000004448 titration Methods 0.000 description 2
235000009434 Actinidia chinensis Nutrition 0.000 description 1
244000298697 Actinidia deliciosa Species 0.000 description 1
235000009436 Actinidia deliciosa Nutrition 0.000 description 1
229920001817 Agar Polymers 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
239000005695 Ammonium acetate Substances 0.000 description 1
101800000734 Angiotensin-1 Proteins 0.000 description 1
102400000344 Angiotensin-1 Human genes 0.000 description 1
229940127291 Calcium channel antagonist Drugs 0.000 description 1
241000282465 Canis Species 0.000 description 1
206010056370 Congestive cardiomyopathy Diseases 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
WDJUZGPOPHTGOT-OAXVISGBSA-N Digitoxin Natural products O([C@H]1[C@@H](C)O[C@@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@@](C)([C@H](C6=CC(=O)OC6)CC5)CC4)CC3)CC2)C[C@H]1O)[C@H]1O[C@@H](C)[C@H](O[C@H]2O[C@@H](C)[C@@H](O)[C@@H](O)C2)[C@@H](O)C1 WDJUZGPOPHTGOT-OAXVISGBSA-N 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
206010061216 Infarction Diseases 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
235000019483 Peanut oil Nutrition 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
206010041277 Sodium retention Diseases 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
208000001871 Tachycardia Diseases 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
239000013543 active substance Substances 0.000 description 1
206010000891 acute myocardial infarction Diseases 0.000 description 1
230000002411 adverse Effects 0.000 description 1
239000008272 agar Substances 0.000 description 1
235000010419 agar Nutrition 0.000 description 1
102000015007 alpha-adrenergic receptor activity proteins Human genes 0.000 description 1
108040006816 alpha-adrenergic receptor activity proteins Proteins 0.000 description 1
229940043376 ammonium acetate Drugs 0.000 description 1
235000019257 ammonium acetate Nutrition 0.000 description 1
239000003708 ampul Substances 0.000 description 1
ORWYRWWVDCYOMK-HBZPZAIKSA-N angiotensin I Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=C(O)C=C1 ORWYRWWVDCYOMK-HBZPZAIKSA-N 0.000 description 1
239000005557 antagonist Substances 0.000 description 1
229940030600 antihypertensive agent Drugs 0.000 description 1
239000002220 antihypertensive agent Substances 0.000 description 1
230000003078 antioxidant effect Effects 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
239000007900 aqueous suspension Substances 0.000 description 1
229960002781 bisoprolol Drugs 0.000 description 1
VHYCDWMUTMEGQY-UHFFFAOYSA-N bisoprolol Chemical compound CC(C)NCC(O)COC1=CC=C(COCCOC(C)C)C=C1 VHYCDWMUTMEGQY-UHFFFAOYSA-N 0.000 description 1
230000036772 blood pressure Effects 0.000 description 1
239000000480 calcium channel blocker Substances 0.000 description 1
PASHVRUKOFIRIK-UHFFFAOYSA-L calcium sulfate dihydrate Chemical compound O.O.[Ca+2].[O-]S([O-])(=O)=O PASHVRUKOFIRIK-UHFFFAOYSA-L 0.000 description 1
230000022900 cardiac muscle contraction Effects 0.000 description 1
229940082638 cardiac stimulant phosphodiesterase inhibitors Drugs 0.000 description 1
230000001848 cardiodepressant effect Effects 0.000 description 1
230000008859 change Effects 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
230000009194 climbing Effects 0.000 description 1
238000007906 compression Methods 0.000 description 1
230000006835 compression Effects 0.000 description 1
238000011443 conventional therapy Methods 0.000 description 1
238000013461 design Methods 0.000 description 1
230000006866 deterioration Effects 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
229960000648 digitoxin Drugs 0.000 description 1
WDJUZGPOPHTGOT-XUDUSOBPSA-N digitoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)CC5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O WDJUZGPOPHTGOT-XUDUSOBPSA-N 0.000 description 1
229940079593 drug Drugs 0.000 description 1
230000009977 dual effect Effects 0.000 description 1
239000000945 filler Substances 0.000 description 1
238000011049 filling Methods 0.000 description 1
235000011187 glycerol Nutrition 0.000 description 1
229940074045 glyceryl distearate Drugs 0.000 description 1
229940075507 glyceryl monostearate Drugs 0.000 description 1
230000001435 haemodynamic effect Effects 0.000 description 1
230000000004 hemodynamic effect Effects 0.000 description 1
230000007574 infarction Effects 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
238000010255 intramuscular injection Methods 0.000 description 1
239000007927 intramuscular injection Substances 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
239000008101 lactose Substances 0.000 description 1
230000003859 lipid peroxidation Effects 0.000 description 1
239000006194 liquid suspension Substances 0.000 description 1
238000011866 long-term treatment Methods 0.000 description 1
239000008176 lyophilized powder Substances 0.000 description 1
230000002101 lytic effect Effects 0.000 description 1
239000000395 magnesium oxide Substances 0.000 description 1
CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
235000012245 magnesium oxide Nutrition 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
239000000463 material Substances 0.000 description 1
238000005259 measurement Methods 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
238000000034 method Methods 0.000 description 1
229960002237 metoprolol Drugs 0.000 description 1
IUBSYMUCCVWXPE-UHFFFAOYSA-N metoprolol Chemical compound COCCC1=CC=C(OCC(O)CNC(C)C)C=C1 IUBSYMUCCVWXPE-UHFFFAOYSA-N 0.000 description 1
208000019267 mild heart failure Diseases 0.000 description 1
208000019266 moderate heart failure Diseases 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000012544 monitoring process Methods 0.000 description 1
230000002107 myocardial effect Effects 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
239000003883 ointment base Substances 0.000 description 1
239000004006 olive oil Substances 0.000 description 1
235000008390 olive oil Nutrition 0.000 description 1
229910052760 oxygen Inorganic materials 0.000 description 1
239000001301 oxygen Substances 0.000 description 1
239000000312 peanut oil Substances 0.000 description 1
239000001814 pectin Substances 0.000 description 1
235000010987 pectin Nutrition 0.000 description 1
229920001277 pectin Polymers 0.000 description 1
230000036513 peripheral conductance Effects 0.000 description 1
239000008024 pharmaceutical diluent Substances 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
239000002571 phosphodiesterase inhibitor Substances 0.000 description 1
230000036314 physical performance Effects 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
239000000843 powder Substances 0.000 description 1
238000004393 prognosis Methods 0.000 description 1
238000005086 pumping Methods 0.000 description 1
238000011160 research Methods 0.000 description 1
235000015598 salt intake Nutrition 0.000 description 1
239000001632 sodium acetate Substances 0.000 description 1
235000017281 sodium acetate Nutrition 0.000 description 1
239000001509 sodium citrate Substances 0.000 description 1
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
239000000243 solution Substances 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
238000013268 sustained release Methods 0.000 description 1
239000012730 sustained-release form Substances 0.000 description 1
210000002820 sympathetic nervous system Anatomy 0.000 description 1
206010042772 syncope Diseases 0.000 description 1
239000000454 talc Substances 0.000 description 1
235000012222 talc Nutrition 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
230000002110 toxicologic effect Effects 0.000 description 1
231100000759 toxicological effect Toxicity 0.000 description 1
230000000304 vasodilatating effect Effects 0.000 description 1
230000024883 vasodilation Effects 0.000 description 1
229940124549 vasodilator Drugs 0.000 description 1
239000003071 vasodilator agent Substances 0.000 description 1
238000005303 weighing Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Cardiology (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Heart & Thoracic Surgery (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Molecular Biology (AREA)
Hospice & Palliative Care (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Indole Compounds (AREA)
Pyrrole Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Saccharide Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

CZ19972463A 1995-02-08 1996-02-07 Léčivo pro snížení úmrtnosti způsobené městnavým selháním srdce u savců CZ292002B6 (cs)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
DE1995103995 DE19503995C2 (de)	1995-02-08	1995-02-08	Verwendung von Carvedilol zur Verminderung der Mortalität bei Patienten mit eingeschränkter myocardialer Funktion
US08/483,635 US5760069A (en)	1995-02-08	1995-06-07	Method of treatment for decreasing mortality resulting from congestive heart failure

Publications (2)

Publication Number	Publication Date
CZ246397A3 CZ246397A3 (cs)	1998-11-11
CZ292002B6 true CZ292002B6 (cs)	2003-07-16

Family

ID=26012210

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CZ19972463A CZ292002B6 (cs)	1995-02-08	1996-02-07	Léčivo pro snížení úmrtnosti způsobené městnavým selháním srdce u savců

Country Status (26)

Country	Link
US (6)	US5760069A (uk)
EP (1)	EP0808162B1 (uk)
JP (1)	JP3546058B2 (uk)
KR (1)	KR100295940B1 (uk)
CN (1)	CN1093760C (uk)
AT (1)	ATE179891T1 (uk)
AU (1)	AU702106C (uk)
BR (1)	BR9607111A (uk)
CA (1)	CA2212548C (uk)
CZ (1)	CZ292002B6 (uk)
DE (1)	DE69602424T2 (uk)
DK (1)	DK0808162T3 (uk)
ES (1)	ES2134588T3 (uk)
FI (1)	FI973255A7 (uk)
GR (1)	GR3030966T3 (uk)
HU (1)	HUP9900773A3 (uk)
NO (1)	NO314830B1 (uk)
NZ (1)	NZ301692A (uk)
PL (1)	PL321737A1 (uk)
RO (1)	RO121629B1 (uk)
RU (1)	RU2197242C2 (uk)
SI (1)	SI0808162T1 (uk)
SK (1)	SK106897A3 (uk)
UA (1)	UA55382C2 (uk)
WO (1)	WO1996024348A2 (uk)
ZA (1)	ZA96994B (uk)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5760069A (en) *	1995-02-08	1998-06-02	Boehringer Mannheim Pharmaceuticals Corporation-Smithkline Beecham Corporation Limited Partnership #1	Method of treatment for decreasing mortality resulting from congestive heart failure
CN1157188C (zh) *	1996-10-09	2004-07-14	泊灵格曼海姆药品公司	抑制应激活化蛋白激酶的方法
ZA989365B (en) *	1997-10-15	1999-04-15	Boehringer Mannheim Pharm Corp	Preparation for treating alzheimer's disease
TR200001362T2 (tr) *	1997-11-12	2000-09-21	Boehringer Mannheim Pharm Corp.-Smithkline Beckman	Yeni karvedilol oral dozaj formu
US20020054911A1 (en) *	2000-05-11	2002-05-09	Boehringer Mannheim Pharmaceutical Corporation-Sm Ithkline Beckman Corporation, Limited Partnershi	Novel oral dosage form for carvedilol
DE19833119A1 (de) *	1998-07-23	2000-01-27	Roche Diagnostics Gmbh	Spritzfertige Injektionslösungen enthaltend Carvedilol
US6664284B2 (en)	1998-07-23	2003-12-16	Roche Diagnostics Gmbh	Stabilized carvedilol injection solution
PE20001302A1 (es) *	1998-11-27	2000-11-30	Hoffmann La Roche	Preparaciones de una combinacion farmaceutica que contiene carvedilol e hidroclorotiazida
WO2001017528A1 (en) *	1999-09-08	2001-03-15	Nitromed, Inc.	Methods of treating and preventing congestive heart failure with hydralazine compounds and isosorbide dinitrate or isosorbide mononitrate
US6635273B1 (en) *	1999-10-29	2003-10-21	Trustees Of Boston University	Methods of treating vascular diseases characterized by nitric oxide insufficiency
US7537785B2 (en) *	1999-10-29	2009-05-26	Nitromed, Inc.	Composition for treating vascular diseases characterized by nitric oxide insufficiency
US7708989B2 (en) *	1999-10-29	2010-05-04	Nitromed, Inc.	Methods of treating vascular diseases characterized by nitric oxide insufficiency
US7235237B2 (en) *	1999-10-29	2007-06-26	Nitromed, Inc.	Methods of treating vascular diseases characterized by nitric oxide insufficiency
US20010036959A1 (en) *	2000-04-03	2001-11-01	Gabel Rolf Dieter	Carvedilol-hydrophilic solutions
JP2004501191A (ja)	2000-06-28	2004-01-15	テバ　ファーマシューティカル　インダストリーズ　リミティド	カルベジロール
WO2002078692A1 (en) *	2001-04-02	2002-10-10	Smithkline Beecham Corporation	Method of treatment
WO2003028718A1 (en) *	2001-10-01	2003-04-10	Smithkline Beecham Corporation	Novel formulations of carvedilol
AU2002341924A1 (en) *	2001-10-02	2003-04-14	Smithkline Beecham Corporation	Novel composition of carvedilol
US8101209B2 (en)	2001-10-09	2012-01-24	Flamel Technologies	Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
SE0103749D0 (sv) *	2001-11-08	2001-11-08	Sahltech Ab	Treatment of congestive heart failure
MXPA04006909A (es)	2002-01-15	2005-04-19	Teva Pharma	Solidos cristalinos de carvedilol y procesos para su preparacion.
EP2316468A1 (en)	2002-02-22	2011-05-04	Shire LLC	Delivery system and methods for protecting and administering dextroamphetamine
RU2203063C1 (ru) *	2002-03-12	2003-04-27	Нестерук Владимир Викторович	Способ получения твердой лекарственной формы препарата, обладающего диуретическим действием
EP1499310A4 (en) *	2002-04-30	2005-12-07	Sb Pharmco Inc	MONOCITRATE MONOHYDRATE OF CARVEDILOL
US6951880B2 (en) *	2002-05-16	2005-10-04	Genelabs Technologies, Inc.	Aryl and heteroaryl compounds as antibacterial and antifungal agents
JP2005533822A (ja) *	2002-06-27	2005-11-10	エスビー・ファルムコ・プエルト・リコ・インコーポレイテッド	臭化水素酸カルベジロール
MXPA04012923A (es) *	2002-06-27	2005-03-31	Sb Pharmco Inc	Sales de fosfato de carvedilol y/o solvatos de las mismas, composiciones correspondientes y/o metodos de tratamiento.
EP1362590B1 (en) *	2002-07-25	2004-01-07	Boehringer Ingelheim Pharma GmbH & Co.KG	Use of cilobradine or the pharmaceutically acceptable salts thereof for the treatment or prevention of heart failure
US6632832B1 (en)	2002-09-10	2003-10-14	Dabur Research Foundation	Anti-cancer activity of carvedilol and its isomers
US20050032879A1 (en) *	2003-08-07	2005-02-10	Temple Okarter	Formulations and use of a beta-blocker and an ACE-inhibitor for the treatment of cardiovascular diseases
JP2007512372A (ja) *	2003-11-25	2007-05-17	エスビー・ファルムコ・プエルト・リコ・インコーポレイテッド	カルベジロール塩、対応する組成物、送達および／または治療方法
CA2547137A1 (en) *	2003-11-25	2005-06-09	Sb Pharmco Puerto Rico Inc.	Carvedilol free base, salts, anhydrous forms or solvates thereof, corresponding pharmaceutical compositions, controlled release formulations, and treatment or delivery methods
EP1686967A4 (en) *	2003-11-25	2012-08-08	Smithkline Beecham Cork Ltd	CARVEDILOL-FREE BASE, SALTS, WATER-FREE FORMS OR SOLVATES THEREOF, CORRESPONDING PHARMACEUTICAL COMPOSITIONS, CONTROLLED RELEASE FORMULAS AND TREATMENT OR DISPOSAL PROCEDURES
EP1778267A4 (en) *	2004-07-16	2010-01-06	Nitromed Inc	COMPOSITIONS AND METHODS RELATED TO HEART ERROR
US20070043099A1 (en) *	2005-06-09	2007-02-22	Igor Lifshitz	Crystalline forms of carvedilol and processes for their preparation
AU2007217980A1 (en) *	2006-02-17	2007-08-30	Nitromed, Inc.	Methods using hydralazine compounds and isosorbide dinitrate or isosorbide mononitrate
US8367112B2 (en) *	2006-02-28	2013-02-05	Alkermes Pharma Ireland Limited	Nanoparticulate carverdilol formulations
US8703804B2 (en) *	2006-03-26	2014-04-22	Uti Limited Partnership	Ryanodine receptor inhibitors and methods relating thereto
EP2024337A4 (en) *	2006-05-16	2011-09-14	Nitromed Inc	SOLID DOSAGE FORMULATIONS OF HYDRALAZIN COMPOUNDS
WO2008002683A2 (en) *	2006-06-28	2008-01-03	Teva Pharmaceutical Industries Ltd.	Polymorphous forms of carvedilol phosphate
US20080207726A1 (en) *	2007-02-26	2008-08-28	Santiago Ini	Process for the purification of carvedilol or its salts thereof
US20090076116A1 (en) *	2007-09-13	2009-03-19	Protia, Llc	Deuterium-enriched carvediolo
CA2724540C (en)	2008-05-16	2014-07-08	Corthera, Inc.	Treating dyspnea associated with acute heart failure with relaxin
EP2558437B1 (en) *	2010-04-12	2015-08-05	Supernus Pharmaceuticals, Inc.	Methods for producing viloxazine salts and novel polymorphs thereof
WO2013024036A1 (en)	2011-08-12	2013-02-21	Boehringer Ingelheim Vetmedica Gmbh	Funny current (if) inhibitors for use in a method of treating and preventing heart failure in feline
CN110381929A (zh) *	2016-06-13	2019-10-25	阿森迪亚制药有限责任公司	卡维地洛分散系统的肠胃外缓释传递
US10772869B1 (en)	2019-07-24	2020-09-15	ECI Pharmaceuticals, LLC	Pharmaceutical compositions including carvedilol and methods of using the same

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE2815926A1 (de) *	1978-04-13	1979-10-18	Boehringer Mannheim Gmbh	Neue carbazolyl-(4)-oxy-propanolamin-derivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
DE3319027A1 (de)	1983-05-26	1984-11-29	Boehringer Mannheim Gmbh, 6800 Mannheim	Verfahren zur herstellung von optisch aktiven carbazol-derivaten, neue r- und s-carbazol-derivate, sowie arzneimittel, die diese verbindungen enthalten
SE460945B (sv) *	1987-01-15	1989-12-11	Lejus Medical Ab	En multipel-unit-dos komposition av furosemid
RU2058144C1 (ru) *	1988-12-15	1996-04-20	Центр по химии лекарственных средств	Средство для лечения сердечной недостаточности
US5312828A (en) *	1989-06-14	1994-05-17	Finkelstein Joseph A	Substituted imidazoles having angiotensin II receptor blocking activity
US5225401A (en) *	1991-08-12	1993-07-06	E. R. Squibb & Sons, Inc.	Treatment of congestive heart failure
RU2032685C1 (ru) *	1991-12-16	1995-04-10	Центр по химии лекарственных средств	Производные пиридо (3,2-а)карбазола, обладающие кардиотонической активностью
US5308862A (en) *	1993-03-05	1994-05-03	Boehringer Mannheim Pharmaceuticals Corporation - Smithkline Beecham Corp., Ltd. Partnership No. 1	Use of, and method of treatment using, carbazolyl-(4)-oxypropanolamine compounds for inhibition of smooth muscle cell proliferation
US5760069A (en)	1995-02-08	1998-06-02	Boehringer Mannheim Pharmaceuticals Corporation-Smithkline Beecham Corporation Limited Partnership #1	Method of treatment for decreasing mortality resulting from congestive heart failure

1995
- 1995-06-07 US US08/483,635 patent/US5760069A/en not_active Ceased
1996
- 1996-02-07 WO PCT/EP1996/000498 patent/WO1996024348A2/en not_active Ceased
- 1996-02-07 BR BR9607111A patent/BR9607111A/pt not_active Application Discontinuation
- 1996-02-07 RU RU97114836/14A patent/RU2197242C2/ru not_active IP Right Cessation
- 1996-02-07 ES ES96902984T patent/ES2134588T3/es not_active Expired - Lifetime
- 1996-02-07 HU HU9900773A patent/HUP9900773A3/hu unknown
- 1996-02-07 SK SK1068-97A patent/SK106897A3/sk unknown
- 1996-02-07 RO RO97-01454A patent/RO121629B1/ro unknown
- 1996-02-07 DE DE69602424T patent/DE69602424T2/de not_active Ceased
- 1996-02-07 NZ NZ301692A patent/NZ301692A/xx not_active IP Right Cessation
- 1996-02-07 SI SI9630081T patent/SI0808162T1/xx not_active IP Right Cessation
- 1996-02-07 CA CA002212548A patent/CA2212548C/en not_active Expired - Fee Related
- 1996-02-07 AT AT96902984T patent/ATE179891T1/de not_active IP Right Cessation
- 1996-02-07 CZ CZ19972463A patent/CZ292002B6/cs not_active IP Right Cessation
- 1996-02-07 PL PL96321737A patent/PL321737A1/xx unknown
- 1996-02-07 JP JP52398296A patent/JP3546058B2/ja not_active Expired - Lifetime
- 1996-02-07 US US08/875,603 patent/US5902821A/en not_active Ceased
- 1996-02-07 EP EP96902984A patent/EP0808162B1/en not_active Expired - Lifetime
- 1996-02-07 CN CN96192902A patent/CN1093760C/zh not_active Expired - Fee Related
- 1996-02-07 US US10/721,022 patent/USRE40707E1/en not_active Expired - Lifetime
- 1996-02-07 DK DK96902984T patent/DK0808162T3/da active
- 1996-02-07 KR KR1019970705480A patent/KR100295940B1/ko not_active Expired - Lifetime
- 1996-02-07 AU AU47181/96A patent/AU702106C/en not_active Revoked
- 1996-02-08 ZA ZA9600994A patent/ZA96994B/xx unknown
- 1996-07-02 UA UA97094498A patent/UA55382C2/uk unknown
1997
- 1997-08-07 FI FI973255A patent/FI973255A7/fi unknown
- 1997-08-08 NO NO19973667A patent/NO314830B1/no not_active IP Right Cessation
1999
- 1999-08-11 GR GR990402047T patent/GR3030966T3/el unknown
2001
- 2001-05-23 US US09/863,535 patent/US20010044455A1/en not_active Abandoned
2002
- 2002-12-19 US US10/324,856 patent/US20030105138A1/en not_active Abandoned
2003
- 2003-11-25 US US10/721,020 patent/USRE40000E1/en not_active Expired - Lifetime

Also Published As

Publication number	Publication date
US5760069A (en)	1998-06-02
AU702106B2 (en)	1999-02-11
AU702106C (en)	2005-02-17
USRE40000E1 (en)	2008-01-08
SI0808162T1 (en)	1999-10-31
CZ246397A3 (cs)	1998-11-11
BR9607111A (pt)	1997-11-04
PL321737A1 (en)	1997-12-22
USRE40707E1 (en)	2009-05-05
NZ301692A (en)	2000-09-29
GR3030966T3 (en)	1999-11-30
US5902821A (en)	1999-05-11
WO1996024348A2 (en)	1996-08-15
MX9706042A (es)	1998-06-30
DK0808162T3 (da)	1999-11-15
AU4718196A (en)	1996-08-27
CN1093760C (zh)	2002-11-06
NO973667D0 (no)	1997-08-08
FI973255A0 (fi)	1997-08-07
ATE179891T1 (de)	1999-05-15
WO1996024348A3 (en)	1996-10-03
ES2134588T3 (es)	1999-10-01
HK1014861A1 (en)	1999-10-08
CN1185106A (zh)	1998-06-17
KR100295940B1 (ko)	2001-08-07
RU2197242C2 (ru)	2003-01-27
CA2212548C (en)	1999-08-24
SK106897A3 (en)	1999-03-12
EP0808162A2 (en)	1997-11-26
NO973667L (no)	1997-08-08
JPH10513463A (ja)	1998-12-22
FI973255A7 (fi)	1997-08-07
HUP9900773A2 (hu)	1999-07-28
EP0808162B1 (en)	1999-05-12
DE69602424D1 (de)	1999-06-17
NO314830B1 (no)	2003-06-02
JP3546058B2 (ja)	2004-07-21
RO121629B1 (ro)	2008-01-30
CA2212548A1 (en)	1996-08-15
UA55382C2 (uk)	2003-04-15
HUP9900773A3 (en)	2000-04-28
US20030105138A1 (en)	2003-06-05
ZA96994B (en)	1997-10-27
KR19980702085A (ko)	1998-07-15
US20010044455A1 (en)	2001-11-22
DE69602424T2 (de)	1999-10-07

Legal Events

Date	Code	Title	Description
2000-06-30	PD00	Pending as of 2000-06-30 in czech republic
2008-10-08	MC4A	Patent revocation (annulment)	Effective date: 20080903

Publication	Publication Date	Title
CZ292002B6 (cs)	2003-07-16	Léčivo pro snížení úmrtnosti způsobené městnavým selháním srdce u savců
KR20190116416A (ko)	2019-10-14	원발 담즙성 담관염을 치료하기 위한 화합물 및 방법
US20250099468A1 (en)	2025-03-27	Treating liver disorders with an ssao inhibitor
US7713984B2 (en)	2010-05-11	Pharmaceutical uses
US20110124724A1 (en)	2011-05-26	Use of dronedarone or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for regulating the potasium level in the blood
US20090239844A1 (en)	2009-09-24	Ace inhibitor-vasopressin antagonist combinations
JP2004525941A (ja)	2004-08-26	治療方法
JP2018135278A (ja)	2018-08-30	循環器疾患及び／又はミトコンドリア病の改善用医薬
CN121398832A (zh)	2026-01-23	用于药物疗法的司美格鲁肽
EP1253945B1 (en)	2006-10-04	Ace inhibitor-vasopressin antagonist combinations
WO2021224494A1 (en)	2021-11-11	New treatments of viral infections
MXPA05005344A (es)	2005-08-03	Formulaciones farmaceuticas liquidas que contienen 3,7-diazabiciclo [3,3,1] nonanos para tratar eventos antiarritmicos.
MXPA97006042A (en)	1998-10-30	Use of carbazol compounds for the treatment of cardiac congest insufficiency
HK1014861B (en)	2003-05-30	Use of carbazole compounds in the manufacture of a medicament for the treatment of congestive heart failure
HUP0402593A2 (hu)	2005-04-28	Kariporidból és ramiprilből álló kombinációs készítmény és alkalmazása
AU2015203811A1 (en)	2015-07-30	Use of organic compound for the treatment of noonan syndrome